^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Yinuokai (orelabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
558 Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker
Published date:
11/03/2022
Excerpt:
...18 pts (81.8%, 18/22) had an MYD88 mutation and achieved an ORR of 100% (CR, 55.6%)….This retrospective data suggested that orelabrutinib combined with RM had an encouraging anti-tumor activity in newly diagnosed PCNSL pts, with a toleratable safety profile.
Secondary therapy:
methotrexate
DOI:
https://doi.org/10.1182/blood-2022-165710
